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Nutrition requirement for a premature infant is greater than that of a term infant [1-3]. Richness of bioactive proteins in human milk provides unmatched benefits 
to the growth and development of a prematurely born infant. 
It is a well-recognized fact that human milk’s benefits extend 
beyond nutrition by reducing the risk for both early and late 
complications for the newborn [4]. Achieving the nutrition goal 
for a premature infant is the need of the hour in the neonatal 
intensive care unit (NICU) [4]. Raw human milk is insufficient 
to meet the nutritional demands of a very low birth weight 
(VLBW) preterm infant; studies have shown that feeding of 
unfortified human milk resulted in inadequate weight gain and 
growth [5-7].
Fortifying human milk aids in providing essential 
macronutrients to meet the demand of VLBW infant. At present, 
two types of fortifiers are available in India which are bovine 
milk based or human milk based [8]. Human milk comprises 60% 
whey and 40% casein proteins, which is in contrast to bovine milk, 
where whey is present in nominal quantity (18%) and casein in 
major quantity (80%) which makes bovine milk-based fortifiers 
(BMBFs) to result in the formation of firm coagulum – making it 
difficult for the preterm infants to digest [9,10].
Evidence suggests that for every increase in 10% bovine 
milk-based diet is associated with an 11.8% increase in the risk 
of necrotizing enterocolitis (NEC), there is 21% increase in the 
risk of surgical NEC and 17.9% increase in the risk of sepsis [3]. 
It is also suggested that risk of NEC reduces substantially when 
mother’s own milk or pasteurized donor human milk is used for 
preterm infants [11]. Following exclusively human milk-based diet 
(EHMD) regimen is achievable using a fortifier which is derived 
completely from the human milk [3]. Till recently, availability of 
100% human milk-derived fortifiers (HMDFs) was limited only to 
the USA. For the 1st time in India and Asia, a complete HMDF is 
available to ensure the EHMD. We planned this study to provide 
the evidence on 100% human milk fortifier (HMF) in India.
MATERIALS AND METHODS
A single-center, descriptive cohort study was conducted among 
13 infants (6 males and 7 females) over a period of 4 months 
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between September 2018 and December 2018. Informed consent 
was obtained from the parents. The Institutional Ethics Approval 
was obtained before commencement of the study. Infants who 
were exclusively fed on human milk were chosen for the study, 
to ensure EHMD.
Inclusion criteria for the study were birth weight of 
1000–1500 g and/or <34 weeks’ gestational age (GA), intention 
to receive only human milk, and the ability to adhere to a feeding 
protocol based on the use of mother’s own milk. The infants with 
major congenital gastrointestinal malformations or infants, who 
had received any bovine-based formula fortifier before enrollment 
in the study, were excluded from the study.
As per the standard protocol, total parenteral nutrition was 
started on day 1 and continued till infants tolerated more than 50% 
of the requirements orally. Oral feeds were initiated on day 2; all 
infants received mother’s own milk. HMF was initiated when the 
enteral feed volume reached 100 mL/kg/day. Fortified feeds were 
stopped at discharge. Infants were discharged based on the following 
criteria: 34 weeks’ corrected gestation, breastfeeding adequately or 
tolerating all requirements orally, and weighing at least 1.6 kg.
Neolact Mother’s Milk Fortifier®, 100% HMDF, was 
used in the current study. Since hyperosmolar preparations 
(>400 mOsm/kg) are associated with NEC, the fortifier has been 
designed (maltodextrin free) to maintain lower osmolality than 
the bovine-based HMF [12]. The enzyme amylase, that is present 
in human milk, breaks down maltodextrin, resulting in a higher 
number of osmotically active molecules, which consequently 
increases osmolality. Thus, a maltodextrin-free fortifier prevents 
hyperosmolality [13,14].
Primary outcome measure of the study was feed intolerance 
which was measured as events comprising 3 or more episodes of 
emesis within a 24-h period, abdominal distention is exceeding 
2 cm or more, or gastric residual volume exceeding 50%. The 
number of feeding episodes that required interruptions was 
also recorded [15]. Secondary outcome measure was growth 
outcome which comprised mean gain in weight, length, and head 
circumference at the end of the study. Weight was measured daily, 
while length and head circumference were measured weekly until 
discharge. The growth velocity (g/kg/day) during the study period 
was also calculated. It was calculated as 
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in 
daily increments until discharge, where Wn=Weight in grams on 
day “n” and Wn+1=Weight in grams on the following day [16].
RESULTS
A total of 13 infants were enrolled during the study period. The 
mean GA and birth weight of the infants were 31.64±2.2 weeks 
and 1314.62±110.1 g, respectively. Table 1 enumerates the 
baseline characteristics that were similar across the study subjects. 
The mean age at the initiation of fortification was 10.23±4.9 days, 
and the mean weight was 1273.85±100.8 g.
The mean feed volume was 118.75±15.8 mL/kg. No episodes 
of feed interruptions were reported and 100% HMDF was well 
tolerated by all the infants. The study outcomes at the end of the 
study are presented in Table 2. Further, a mean growth velocity 
of 18.37±5.1 g/kg/day was observed across the study population. 
The absence of feed interruptions and linear growth velocity 
indicates that safe growth was achieved with the HMDF, without 
compromising on growth markers.
DISCUSSION
The number of premature newborns continues to rise in India and 
so is the importance of nutrition to ensure the intact survival [17]. 
Bovine milk has been the source for the multinutrient fortifiers [18]. 
Recently, using lactoengineering techniques, multinutrient 
fortifiers have been derived from human milk instead of bovine 
milk [3]. Since exposure to commercial formula feeds is thought 
to increase the morbidities including NEC, multicomponent 
HMDF has been used to minimize exposure to bovine products. 
HMDF is introduced, once tolerance of feeds at a volume greater 
than trophic feeds is demonstrated. The supplementation with 
HMDF is continued until around 34 weeks when transition to a 
post-discharge transitional formula or a term formula is made. 
There are very few studies available on the use of HMDF.
Cristofalo et al. studied infants with birth weight of  ≤1250 g for 
whom mother’s milk was not available. Infants were randomized 
into two groups. One group received donor HMF with HMDF 
and the other group received formula feeds. Results from this 
study demonstrated a significant reduction in the number of days 
of parenteral nutrition and zero surgical NEC cases in HMDF 
group as compared to formula feed group which had more days in 
parenteral nutrition and four cases of surgical NEC [19].
Sullivan et al. studied the effects of fortification with HMDF 
versus bovine milk-based fortifiers (BMBFs) in VLBW infants 
Table 1: Baseline characteristics of the study subjects
Parameter n=13
Birth weight (g), mean±SD 1314.62±110.1
Gestational age (weeks), mean±SD 31.64±2.2
Male/female, n (%) 6/7 (46/54)
Lower segment cesarean section, n (%) 13 (100)
Continuous positive airway pressure, n (%) 11 (85)
Sepsis, n (%) 3 (23)
Intracranial hemorrhage, n (%) 3 (23)
Hyperbilirubinemia, n (%) 13 (100)
Total parenteral nutrition (days), mean±SD 3.31±3.4
Age at initiation of fortification (days), mean±SD 10.23±4.9
Weight at initiation of fortification (g), mean±SD 1273.85±100.8
SD: Standard deviation
Table 2: Study outcomes (n=13)
Parameter Mean±standard deviation
Weight gain/day (g) 25.97±7.7
Head circumference gain/week (cm) 0.39±0.20
Length gain/week (cm) 0.32±0.23
Growth velocity (g/kg/d) 18.37±5.1
Episodes of feed interruptions 0
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with birth weight of <1250 g (n=207), results demonstrated 
that HMDF group had a decrease in the likelihood of parenteral 
nutrition with a significant reduction in NEC (6% vs. 16%, 
p=0.02). HMDF achieved EHMD with 50% reduction in NEC and 
90% reduction in surgical NEC when compared with the BMBF 
group. Authors concluded that HMDF group had 77% reduction 
in the chances of developing NEC versus the BMBF [3].
Ganapathy et al. assessed the cost-effectiveness of feeding 
extremely premature infants with expressed breast milk fortified 
with BMBF versus 100% HMDF. Results from this study showed 
that there was a significant reduction of overall costs of NICU 
stay with HMDF group when compared with BMBF. Incidence of 
both medical and surgical NEC was low with HMDF and hence 
cost reductions of medical NEC by 2.5 times and surgical NEC by 
7 times when compared with BMBF [20].
Our study revealed that an EHMD fortified with 100% HMDF 
was well tolerated by preterm infants and was beneficial. Since 
the early research results of studies are promising, further studies 
and large trials are required to establish the potential benefits of 
HMDF. A recent consensus statement by the panel on “Human 
milk in feeding premature infants” concluded that HMDFs that 
are currently available are probably of a better quality than 
cow’s milk-based fortifiers [7]. The World Health Organization 
recommends that preterm infants should be fed mother’s own 
milk and donor human milk when a mother’s own breast milk is 
not feasible. Furthermore, the guidelines emphasize that HMFs 
must be preferably HMDF [21].
The study has certain limitations. It was a single-center 
descriptive cohort study; hence, the results may not be amenable 
to generalization. The sample size of the study was small, and 
a larger study, which includes a post-discharge follow-up of the 
infants, is needed to be conducted to reinforce the findings of this 
study.
CONCLUSION
Our study presents evidence that the new 100% HMDF ensures 
EHMD and also is a safe option for the growth of VLBW preterm 
infants. The results indicate good feed tolerance with no clinically 
significant record of adverse events.
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